Analysts at Piper Jaffray Companies assumed coverage on shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in a note issued to investors on Thursday. The brokerage set an “overweight” rating on the biotechnology company’s stock.

Several other analysts also recently weighed in on BMRN. Leerink Swann reaffirmed a “buy” rating on shares of BioMarin Pharmaceutical in a report on Tuesday, July 18th. Zacks Investment Research raised shares of BioMarin Pharmaceutical from a “hold” rating to a “strong-buy” rating and set a $105.00 target price on the stock in a report on Monday, July 17th. Cowen and Company reaffirmed a “buy” rating on shares of BioMarin Pharmaceutical in a report on Tuesday, July 11th. BidaskClub downgraded shares of BioMarin Pharmaceutical from a “hold” rating to a “sell” rating in a report on Monday, July 24th. Finally, Barclays PLC reaffirmed an “equal weight” rating and issued a $100.00 target price (down previously from $105.00) on shares of BioMarin Pharmaceutical in a report on Saturday, July 22nd. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and sixteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $109.22.

BioMarin Pharmaceutical (NASDAQ BMRN) traded up 0.1295% during midday trading on Thursday, hitting $92.8701. 241,985 shares of the stock traded hands. The company’s market cap is $16.28 billion. BioMarin Pharmaceutical has a one year low of $78.42 and a one year high of $101.27. The company’s 50 day moving average is $86.18 and its 200-day moving average is $89.53.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.01. The company had revenue of $317.50 million for the quarter, compared to analyst estimates of $311.41 million. BioMarin Pharmaceutical had a negative net margin of 15.54% and a negative return on equity of 5.77%. BioMarin Pharmaceutical’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the business posted ($2.61) earnings per share. On average, equities research analysts forecast that BioMarin Pharmaceutical will post ($0.70) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “BioMarin Pharmaceutical Inc. (BMRN) Now Covered by Analysts at Piper Jaffray Companies” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/14/biomarin-pharmaceutical-inc-bmrn-given-overweight-rating-at-piper-jaffray-companies.html.

In other BioMarin Pharmaceutical news, Director V Bryan Lawlis sold 3,750 shares of BioMarin Pharmaceutical stock in a transaction dated Friday, June 16th. The shares were sold at an average price of $90.00, for a total transaction of $337,500.00. Following the completion of the transaction, the director now owns 19,660 shares in the company, valued at $1,769,400. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP George Eric Davis sold 9,844 shares of BioMarin Pharmaceutical stock in a transaction dated Friday, June 23rd. The stock was sold at an average price of $96.60, for a total transaction of $950,930.40. Following the transaction, the executive vice president now owns 93,425 shares of the company’s stock, valued at approximately $9,024,855. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 31,265 shares of company stock valued at $2,905,530. 2.50% of the stock is currently owned by company insiders.

Large investors have recently bought and sold shares of the company. Parallel Advisors LLC raised its position in shares of BioMarin Pharmaceutical by 13.6% in the first quarter. Parallel Advisors LLC now owns 1,042 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 125 shares during the last quarter. Korea Investment CORP raised its position in shares of BioMarin Pharmaceutical by 143.5% in the second quarter. Korea Investment CORP now owns 1,595 shares of the biotechnology company’s stock valued at $145,000 after buying an additional 940 shares during the last quarter. Global X Management Co. LLC raised its position in shares of BioMarin Pharmaceutical by 59.7% in the first quarter. Global X Management Co. LLC now owns 1,656 shares of the biotechnology company’s stock valued at $145,000 after buying an additional 619 shares during the last quarter. Mutual of America Capital Management LLC raised its position in shares of BioMarin Pharmaceutical by 20.0% in the first quarter. Mutual of America Capital Management LLC now owns 2,066 shares of the biotechnology company’s stock valued at $181,000 after buying an additional 344 shares during the last quarter. Finally, Toronto Dominion Bank raised its position in shares of BioMarin Pharmaceutical by 12.9% in the second quarter. Toronto Dominion Bank now owns 2,124 shares of the biotechnology company’s stock valued at $193,000 after buying an additional 243 shares during the last quarter. 97.42% of the stock is owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Analyst Recommendations for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.